Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)
Historic EBIT Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 107.87%.
- Keros Therapeutics' EBIT Margin rose 150099200.0% to 107.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.67%, marking a year-over-year increase of 313592900.0%. This contributed to the annual value of 5938.96% for FY2024, which is 1066047500.0% up from last year.
- As of Q3 2025, Keros Therapeutics' EBIT Margin stood at 107.87%, which was up 150099200.0% from 219.16% recorded in Q2 2025.
- Keros Therapeutics' 5-year EBIT Margin high stood at 1576900.0% for Q1 2021, and its period low was 541000.0% during Q3 2023.
- Over the past 5 years, Keros Therapeutics' median EBIT Margin value was 1750.62% (recorded in 2024), while the average stood at 59681.03%.
- As far as peak fluctuations go, Keros Therapeutics' EBIT Margin tumbled by 2000000000bps in 2022, and later surged by 2000000000bps in 2024.
- Quarter analysis of 5 years shows Keros Therapeutics' EBIT Margin stood at 27.18% in 2021, then plummeted by -393bps to 134.03% in 2022, then tumbled by -24137bps to 32486.01% in 2023, then skyrocketed by 95bps to 1750.62% in 2024, then skyrocketed by 94bps to 107.87% in 2025.
- Its EBIT Margin stands at 107.87% for Q3 2025, versus 219.16% for Q2 2025 and 71.97% for Q1 2025.